Regular inhaled short acting β2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis

Thorax

Volumn 58, Issue 7, 2003, Pages 580-584

  Ram, F S F ^a   Sestini, P ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; ORCIPRENALINE; REPROTEROL; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE;

ADULT; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; META ANALYSIS; METERED DOSE INHALER; OUTCOMES RESEARCH; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SPIROMETRY; TREATMENT FAILURE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMANS; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW RATE; PRACTICE GUIDELINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; TREATMENT FAILURE; VITAL CAPACITY;

EID: 0038691866     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.7.580     Document Type: Review

References (24)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am J Respir Crit Care Med 1995;152:S77-120.
2. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398-420.
3. Pauwels RA, Buist AS, Ma P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmanary disease. Respir Care 2001;46:798-825.
4. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee ofthe BTS. Thorax 1997;52(Suppl 5):S1-28.
5. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
6. Guyatt GH, Townsend M, Keller JL, et al. Should study subjects see their previous responses: data from a randomized control trial. J Clin Epidemiol 1989;42:913-20.
7. Guyatt GH, Townsend M, Nogradi S, et al. Acute responses to bronchodilator: an imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern Med 1988;148:1949-52.
8. Jaeschke R, Guyatt GH, Singer J, et al. Mechanism of bronchodilator effect in chronic airflow limitation. Can Med Assoc J 1991;144:35-9.
9. Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest 1986;89:171-3.
10. Klock LE, Miller TD, Morris AH, et al. A comparative study of atropine sulphate and isoproterenol hydrochloride in chronic bronchitis. Am Rev Respir Dis 1975;112:371-6.
11. Light RW, Summer WR, Luchsinger PC. Response of patients with chronic obstructive lung disease to the regular administration of nebulized isoproterenol. Chest 1975;67:634-9.
12. Hansen NC, May O. Domiciliary nebulised terbutaline in severe chronic airways obstruction. Eur Respir J 1990;3:463-4.
13. Silins RA, Marlin GE. Evaluation of domiciliary treatment with terbutaline by wet nebulisation in patients with chronic bronchitis and emphysema. Aust NZ J Med 1985;15:230-4.
14. Tandon MK, Kailis SG. Bronchodilator treatment for partially reversible chronic obstructive airways disease. Thorax 1991;46:248-51.
15. Wilson RS, Connellan SJ. Domicillary nebulised salbutamol solution in severe chronic airway obstruction. Thorax 1980;35:873-6.
16. Shah SS, Johnsonton D, Woodcock AA, et al. Breathlessness and exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly salbutamol by inhalation. Curr Med Res Opin 1983;8:345-9.
17. Taylor DR, Buick B, Kinney C, et al. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985;131:747-51.
18. Cleophas TJ. Carry-over biases in clinical pharmacology. Eur J Clin Chem Clin Biochem 1993;31:803-9.
19. Formgren H, Sjokvist A, Stahl E, et al. Terbutaline in COPD comparison between turbuhaler and chloroflurocarbon (CFC) inhaler. Lung 1994;172:271-80.
20. Ikeda A, Nishimura K, Koyama H, et al. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration 1999;66:119-23.
21. Iversen ET, Sorensen T, Heckscher T, et al. Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease. Lung 1999;177:263-71.
22. Mutterlein VR, Schmidt G, Fleischer W, et al. A new inhalation system for bronchodilation. A study of the acceptance of the Ingelheim M inhalator by chronic obstructive pulmonary disease patients. Fortscritte Therapie (Pneumologie) 1990;108:225/61-8/66.
23. Appleton S, Smith B, Veale A, et al. Long-acting beta2-agonists for chronic obstructive pulmonary disease. In: Cochrane Database Syst Rev 2000: Issue 2.
24. Cook D, Guyatt G, Wang E, et al. Regular versus as-needed short, acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:85-90.